Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9
Benzinga Newsdesk 5 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Raymond James analyst Ryan Deschner upgrades InflaRx (NASDAQ:IFRX) from Outperform to Strong Buy and raises the price target from $7 to $9.
Raymond James analyst Ryan Deschner upgrades InflaRx (NASDAQ:IFRX) from Outperform to Strong Buy and raises the price target from $7 to $9.